Shire PLC  

(Public, LON:SHP)   Watch this stock  
Find more results for SHP
3,555.48
+75.48 (2.17%)
Feb 10 - Close
LON real-time data - Disclaimer
Currency in GBX unless noted
Range 3,469.00 - 3,633.00
52 week 3,466.00 - 5,870.00
Open 3,509.00
Vol / Avg. 2.29M/2.15M
Mkt cap 21.17B*
P/E 9.97
Div/yield 2.69*
EPS 3.57*
Shares 592.59M
Beta     -
Inst. own     -
*GBP
Apr 29, 2016
Q1 2016 Shire PLC Earnings Release Add to calendar
Apr 27, 2016
Shire PLC Annual Shareholders Meeting (Estimated) - 2:45PM GMT+1 - Add to calendar
Feb 11, 2016
Full Year 2015 Shire PLC Earnings Call - 2:00PM GMT - Add to calendar
Feb 11, 2016
Full Year 2015 Shire PLC Earnings Release Add to calendar
Jan 12, 2016
Shire PLC at JPMorgan Healthcare Conference (Q&A Session)
Jan 12, 2016
Shire PLC at JPMorgan Healthcare Conference
Dec 3, 2015
Shire PLC at Deutsche Bank dbAccess Pharmaceutical Corporate Day
Dec 1, 2015
Shire PLC at Piper Jaffray Healthcare Conference
Nov 18, 2015
Shire PLC at Jefferies Global Healthcare Conference
  

Key stats and ratios

Q3 (Sep '15) 2014
Net profit margin 28.87% 54.47%
Operating margin 27.54% 28.20%
EBITD margin - 41.79%
Return on average assets 11.11% 29.88%
Return on average equity 20.50% 46.80%
Employees 5,016 -
CDP Score - 91 B

Address

5 Riverwalk Citywest Business Campus, Dublin 24
DUBLIN,
Ireland
+353-1-4297700 (Phone)
+353-1-4297701 (Fax)

Website links

External links

Analyst Estimates - BusinessWeek
Options - MarketWatch
Director Dealings - Yahoo Finance

Description

Shire plc is a biopharmaceutical company. The Company, along with its subsidiaries, is engaged in developing and marketing medicines for patients with rare diseases and other specialty conditions. The Company commercializes its products in the areas of Neuroscience, Gastrointestinal (GI), Rare Diseases and Other therapeutic areas. The Company’s products include VYVANSE/VENVANSE/ELVANSE/TYVENSE/ELVANSE VUXEN/ADUVANZ (lisdexamfetamine dimesylate), ADDERALL XR (mixed salts of a single-entity amphetamine), INTUNIV (extended release guanfacine), EQUASYM (methylphenidate hydrochloride) modified release (XL), BUCCOLAM, LIALDA (mesalamine)/ MEZAVANT(mesalazine), PENTASA (mesalamine), RESOLOR (prucalopride), REPLAGAL (agalsidase alfa), VPRIV (velaglucerase alfa), FIRAZYR (icatibant), CINRYZE C1 esterase inhibitor (human), FOSRENOL (lanthanum carbonate), XAGRID/ AGRYLIN (anagrelide hydrochloride) and PLENADREN (modified release hydrocortisone).

Officers and directors

Flemming Ornskov M.D. Chief Executive Officer, Executive Director
Age: 57
Jeffrey Poulton Chief Financial Officer, Director
Age: 47
Ginger Gregory Chief Human Resource Officer
Mark J. Enyedy Interim General Counsel, Head of Corporate Development
Age: 51
Phil J. Vickers Head of Research and Development
Age: 55
Susan Saltzbart Kilsby Non-Executive Chairman of the Board
Age: 56
David J. Kappler Senior Independent Non-Executive Deputy Chairman of the Board
Age: 68
Olivier Bohuon Non-Executive Director
Age: 56
Sara Mathew Non-Executive Director
Age: 60
Dominic Blakemore Non-Executive Independent Director
Age: 45